InterAx Biotech AG, a spin-off company of the Paul Scherrer Institute and ETH, is setting new standards in drug development with its advanced AI platform. By uncovering novel cellular signalling pathways, the company is paving the way for innovative therapies in the fields of diabetes, obesity and immuno-oncology.
InterAx Biotech AG has made particularly promising progress in the development of an oral alternative to tirzepatide for metabolic disorders and weight loss. InterAx uses a combination of biochemistry, mathematical modelling and AI to identify novel cellular mechanisms for drug development, leading to therapies with improved efficacy and safety profiles. In the field of immuno-oncology in particular, InterAx has discovered a compound that improves the immune response against tumours by normalising cytokine levels within the tumour. This could significantly improve the effectiveness of immunotherapies and other cancer treatments. The company works closely with pharmaceutical companies and is led by a team of experienced scientists and executives.
